RedHill Biopharma, a US-based specialty biopharmaceutical company, has announced the licensing of Talicia for new Middle East markets in a deal worth potentially $1.8 million plus sales royalty payments.
Under the terms of the agreement, RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months. In addition, RedHill may receive a minimum of $1.3 million in near-term potential milestone payments, as well as tiered royalties up to mid-teens percent on Talicia net sales.
Rick Scruggs, RedHill's Chief Commercial Officer said, "RedHill is committed to expanding patient access to Talicia globally and we now have an excellent opportunity for market building in the region, where we know there is a significant medical need for effective H. pylori treatment. Additional geographic expansion efforts are also ongoing to broaden market access and to secure additional non-dilutive ex-US licensing revenue streams."
Talicia is a leading H. pylori therapy prescribed by US gastroenterologists. It is listed as a first-line option for the treatment of H. pylori infection in the American College of Gastroenterology (ACG) Clinical Guideline, Talicia is the only US FDA-approved all-in-one, low-dose rifabutin-based therapy designed to address H. pylori resistance to other antibiotics commonly used in H. pylori therapies.
Talicia is patent protected through 2042 and received eight years of US market exclusivity under its Qualified Infectious Disease Product (QIDP) designation.
